Two recent graduates share strategies for standing out in the competitive fellowship application process.
Opinion|Videos|November 5, 2024
Behind the Counter: Mastering Pseudoephedrine and Other Restricted OTC Medications
Author(s)Melissa Zinszer, PharmD, CDCES
Melissa Zinszer, PharmD, CDCES, explores the multifaceted role of pharmacists and healthcare providers in managing behind-the-counter medications, addressing patient concerns, optimizing over-the-counter therapy, and ensuring safe, effective treatment through careful symptom assessment and consideration of drug interactions.
Advertisement
Advertisement
Related to this article
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
This quiz was created in collaboration with PTCE™.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
2
Pharmacists Positioned as Key Educators as Monoclonal Antibodies Emerge as COVID-19 Immunization Option
3
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
4
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
5